Advocate1955's MedHelp Blogs http://www.medhelp.org/user_journals/show/1739543 Medical communities and forums staffed by doctors from leading medical centers. Over 325 forums and communities providing medical information and medical help. en EASL 2014: Final Phase II data from Interferon-free COSMOS Study Below please find data from Phase II of the Interferon-free Cosmos study presented at EASL 2014 in Lo Advocate1955 Mon, 14 Apr 2014 06:14:51 -0500 http://www.medhelp.org/user_journals/show/1058321/EASL-2014--Final-Phase-II-data-from-Interferon-free-COSMOS-Study http://www.medhelp.org/user_journals/show/1058321/EASL-2014--Final-Phase-II-data-from-Interferon-free-COSMOS-Study Ledipasvir-Sofosbuvir, 94-99% SVR rate for HCV G1 previous non responders Below is an article that came out on 4/12/14 in the New England Journal of Medicine summarizing resul Advocate1955 Sat, 12 Apr 2014 16:57:26 -0500 http://www.medhelp.org/user_journals/show/1057716/Ledipasvir-Sofosbuvir--94-99-SVR-rate-for-HCV-G1-previous-non-responders http://www.medhelp.org/user_journals/show/1057716/Ledipasvir-Sofosbuvir--94-99-SVR-rate-for-HCV-G1-previous-non-responders Recommendations for Testing, Managing, and Treating Hepatitis C from AASLD and IDSA Below are two sections from the recently released AASLD and IDSA recommendations for testing, managin Advocate1955 Sun, 09 Feb 2014 11:27:07 -0600 http://www.medhelp.org/user_journals/show/1009539/Recommendations-for-Testing--Managing--and-Treating-Hepatitis-C-from-AASLD-and-IDSA http://www.medhelp.org/user_journals/show/1009539/Recommendations-for-Testing--Managing--and-Treating-Hepatitis-C-from-AASLD-and-IDSA Appointment with Hepatologist on 12/5/13 My husband saw his hepatologist for a routine follow up (labs, imaging, check up) earlier this month Advocate1955 Thu, 26 Dec 2013 11:41:09 -0600 http://www.medhelp.org/user_journals/show/989565/Appointment-with-Hepatologist-on-12-5-13 http://www.medhelp.org/user_journals/show/989565/Appointment-with-Hepatologist-on-12-5-13 AASLD 2013: sofosbuvir & ledipasvir with or without ribavirin According to information presented at AASLD 2013 in Washington D.C., results of the LONESTAR study de Advocate1955 Thu, 28 Nov 2013 11:34:37 -0600 http://www.medhelp.org/user_journals/show/964210/AASLD-2013--sofosbuvir--ledipasvir-with-or-without-ribavirin http://www.medhelp.org/user_journals/show/964210/AASLD-2013--sofosbuvir--ledipasvir-with-or-without-ribavirin AASLD 2013: sofosbuvir, ledispavir plus ribavirin or GS9669 According to information presented at AASLD 2013 in Washington D.C. this month, results of the ELECTR Advocate1955 Thu, 28 Nov 2013 11:25:51 -0600 http://www.medhelp.org/user_journals/show/964209/AASLD-2013--sofosbuvir--ledispavir-plus-ribavirin-or-GS9669 http://www.medhelp.org/user_journals/show/964209/AASLD-2013--sofosbuvir--ledispavir-plus-ribavirin-or-GS9669 AASLD 2013: Simeprevir + Sofosbuvir According to information presented at AASLD 2013 in Washington, D.C. this month, results of the Phase Advocate1955 Thu, 28 Nov 2013 11:04:00 -0600 http://www.medhelp.org/user_journals/show/964204/AASLD-2013-Simeprevir--Sofosbuvir- http://www.medhelp.org/user_journals/show/964204/AASLD-2013-Simeprevir--Sofosbuvir- EASL 2013, International Liver Conference, AbbVie AbbVie reported results of a trial involving a 12 week regimen of 3 drugs combined with RBV trials (9 Advocate1955 Sun, 28 Apr 2013 14:09:52 -0500 http://www.medhelp.org/user_journals/show/751088/EASL-2013--International-Liver-Conference--AbbVie http://www.medhelp.org/user_journals/show/751088/EASL-2013--International-Liver-Conference--AbbVie EASL 2013, International Liver Conference, Janssen Janssen R & D (Ireland) reported results of two Phase 3 trials, G1 & G2, treatment naive, simeprevir. Advocate1955 Sun, 28 Apr 2013 14:04:00 -0500 http://www.medhelp.org/user_journals/show/751085/EASL-2013--International-Liver-Conference--Janssen http://www.medhelp.org/user_journals/show/751085/EASL-2013--International-Liver-Conference--Janssen EASL 2013, International Liver Conference, Boehringer Ingelheim Boehringer Ingelheim reported results of one Phase 3 trial, STARTVerso at the EASL 2013 International Advocate1955 Sun, 28 Apr 2013 13:59:48 -0500 http://www.medhelp.org/user_journals/show/751083/EASL-2013--International-Liver-Conference--Boehringer-Ingelheim http://www.medhelp.org/user_journals/show/751083/EASL-2013--International-Liver-Conference--Boehringer-Ingelheim EASL 2013, International Liver Conference, Gilead Gilead reported results on four phase 3 trials with sofosbuvir at EASL 2013, International Liver Conf Advocate1955 Sun, 28 Apr 2013 13:54:50 -0500 http://www.medhelp.org/user_journals/show/751082/EASL-2013--International-Liver-Conference--Gilead http://www.medhelp.org/user_journals/show/751082/EASL-2013--International-Liver-Conference--Gilead Link to Hep C Survival Guide Copyman, another member of this forum, posted this link to a Hep C Survival Guide a couple of days ag Advocate1955 Wed, 26 Dec 2012 12:01:42 -0600 http://www.medhelp.org/user_journals/show/634676/Link-to-Hep-C-Survival-Guide http://www.medhelp.org/user_journals/show/634676/Link-to-Hep-C-Survival-Guide Regular marijuana use increases risk of Hep C related liver damage Thank you to mikesimon for sharing this article. I am posting it in my journal for reference. Advoc Advocate1955 Wed, 19 Dec 2012 07:45:31 -0600 http://www.medhelp.org/user_journals/show/628735/Regular-marijuana-use-increases-risk-of-Hep-C-related-liver-damage http://www.medhelp.org/user_journals/show/628735/Regular-marijuana-use-increases-risk-of-Hep-C-related-liver-damage Preparing for first appointment with hepatologist Here is a copy of a list that Orphaned Hawk posted in her journal and a list that Hector SF posted Advocate1955 Wed, 05 Dec 2012 07:55:20 -0600 http://www.medhelp.org/user_journals/show/615811/Preparing-for-first-appointment-with-hepatologist http://www.medhelp.org/user_journals/show/615811/Preparing-for-first-appointment-with-hepatologist Follow up with Hepatologist, Nov, 2012 Saw hepatologist last week. News is good. Liver is compensated, no sign of cancer, labs good. CT Advocate1955 Sat, 01 Dec 2012 15:03:56 -0600 http://www.medhelp.org/user_journals/show/610936/Follow-up-with-Hepatologist--Nov--2012 http://www.medhelp.org/user_journals/show/610936/Follow-up-with-Hepatologist--Nov--2012 Bristol-Myers Squibb Co., Phase 2 Data, Asunaprevir & Daclatasvir, up to 78% SVR rate in G1b previous null responders Bristol-Myers Squibb Company (BMS) announced yesterday at the Liver Meeting in Boston, Nov. 2012, tha Advocate1955 Mon, 12 Nov 2012 09:00:14 -0600 http://www.medhelp.org/user_journals/show/588318/Bristol-Myers-Squibb-Co--Phase-2-Data--Asunaprevir--Daclatasvir--up-to-78-SVR-rate-in-G1b-previous-null-responders http://www.medhelp.org/user_journals/show/588318/Bristol-Myers-Squibb-Co--Phase-2-Data--Asunaprevir--Daclatasvir--up-to-78-SVR-rate-in-G1b-previous-null-responders Abbott's triple DAA regimen plus Ribavirin, 12 weeks, high rates of SVR in both treatment naive and null responders This information has already been posted on the Hep C forum, but I wanted to post it in my journals f Advocate1955 Sun, 11 Nov 2012 12:18:00 -0600 http://www.medhelp.org/user_journals/show/587516/Abbotts-triple-DAA-regimen-plus-Ribavirin--12-weeks--high-rates-of-SVR-in-both-treatment-naive-and-null-responders http://www.medhelp.org/user_journals/show/587516/Abbotts-triple-DAA-regimen-plus-Ribavirin--12-weeks--high-rates-of-SVR-in-both-treatment-naive-and-null-responders Boehringer Ingelheim's faldaprevir (BI201335), up to 85% SVR in treatment naive Boehringer Ingelheim (BI) announced that faldaprevir (BI201335) and BI207127 combined with Ribavirin Advocate1955 Sun, 11 Nov 2012 11:36:00 -0600 http://www.medhelp.org/user_journals/show/587498/Boehringer-Ingelheims-faldaprevir-BI201335--up-to-85-SVR-in-treatment-naive http://www.medhelp.org/user_journals/show/587498/Boehringer-Ingelheims-faldaprevir-BI201335--up-to-85-SVR-in-treatment-naive Merck's MK-5172 Phase 2 study, protease inhibitor, 96% SVR12 Merck announced that 96% of trial patients achieved SVR12 with it's protease inhibitor (MK-5172) comb Advocate1955 Sun, 11 Nov 2012 11:09:29 -0600 http://www.medhelp.org/user_journals/show/587495/Mercks-MK-5172-Phase-2-study--protease-inhibitor--96-SVR12 http://www.medhelp.org/user_journals/show/587495/Mercks-MK-5172-Phase-2-study--protease-inhibitor--96-SVR12 Gilead's Sofosbuvir (GS-7977), 100% SVR4 in treatment naive G1's This has already been posted by Orphaned Hawk on the Hep C forum, but I thought it might be a good id Advocate1955 Sun, 11 Nov 2012 11:00:53 -0600 http://www.medhelp.org/user_journals/show/587492/Gileads-Sofosbuvir-GS-7977--100-SVR4-in-treatment-naive-G1s http://www.medhelp.org/user_journals/show/587492/Gileads-Sofosbuvir-GS-7977--100-SVR4-in-treatment-naive-G1s